Minichromosome maintenance protein 6, a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphoma

British Journal of Cancer

Volumn 93, Issue 8, 2005, Pages 939-945

  Schrader, C ^a   Janssen, D ^a   Klapper, W ^a   Siebmann, J U ^a   Meusers, P ^b   Brittinger, G ^b   Kneba, M ^a   Tiemann, M ^a   Parwaresch, R ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Cell cycle; Ki 67; Mantle cell lymphoma (MCL); Minichromosome maintenance protein 6 (MCM6); Proliferation

Indexed keywords

KI 67 ANTIGEN; MINICHROMOSOME MAINTENANCE PROTEIN 6; MONOCLONAL ANTIBODY; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE G1 PHASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE BIOPSY; MANTLE CELL LYMPHOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL;

BIOPSY; CELL CYCLE PROTEINS; CELL PROLIFERATION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPH NODES; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 27144450587     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602795     Document Type: Article

References (48)

1. Bertoni F, Zucca E, Cavalli F (2004) Mantle cell lymphoma. Curr Opin Hematol 11: 411-418
2. Brake T, Connor JP, Petereit DG, Lambert PF (2003) Comparative analysis of cervical cancer in women and in a human papillomavirus-transgenic mouse model: identification of minichromosome maintenance protein 7 as an informative biomarker for human cervical cancer. Cancer Res 63: 8173-8180
3. Brittinger G, Bartels H, Common H, Duhmke E, Fulle HH, Gunzer U, Gyenes T, Heinz R, Konig E, Meusers P (1984) Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas. Results of a prospective multicenter study by the Kiel Lymphoma Study Group. Hematol Oncol 2: 269-306
4. Campo E, Raffeld M, Jaffe ES (1999) Mantle-cell lymphoma. Semin Hematol 36: 115-127
5. Chatrath P, Scott IS, Morris LS, Davies RJ, Rushbrook SM, Bird K, Vowler SL, Grant JW, Saeed IT, Howard D, Laskey RA, Coleman N (2003) Aberrant expression of minichromosome maintenance protein-2 and Ki67 in laryngeal squamous epithelial lesions. Br J Cancer 89: 1048-1054
6. Davidson EJ, Morris LS, Scott IS, Rushbrook SM, Bird K, Laskey RA, Wilson GE, Kitchener HC, Coleman N, Stern PL (2003) Minichromosome maintenance (Mem) proteins, cyclin B1 and D1, phosphohistone H3 and in situ DNA replication for functional analysis of vulval intraepithelial neoplasia. Br J Cancer 88: 257-262
7. Dudderidge TJ, Stoeber K, Loddo M, Atkinson G, Fanshawe T, Griffiths DF, Williams GH (2005) Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res 11: 2510-2517
8. Ek S, Bjorck E, Porwit-MacDonald A, Nordenskjold M, Borrebaeck CA (2004) Increased expression of Ki-67 in mantle cell lymphoma is associated with de-regulation of several cell cycle regulatory components, as identified by global gene expression analysis. Haematologica 89: 686-695
9. Eward KL, Obermann EC, Shreeram S, Loddo M, Fanshawe T, Williams C, Jung HI, Prevost AT, Blow JJ, Stoeber K, Williams GH (2004) DNA replication licensing in somatic and germ cells. J Cell Sci 117: 5875-5886
10. Freeman A, Morris LS, Mills AD, Stoeber K, Laskey RA, Williams GH, Coleman N (1999) Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res 5: 2121-2132
11. Fujita M, Kiyono T, Hayashi Y, Ishibashi M (1997) In vivo interaction of human MCM heterohexameric complexes with chromatin. Possible involvement of ATP. J Biol Chem 272: 10928-10935
12. Going JJ, Keith WN, Neilson L, Stoeber K, Stuart RC, Williams GH (2002) Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett's mucosa. Gut 50: 373-377
13. Gonzalez MA, Tachibana KE, Chin SF, Callagy G, Madine MA, Vowler SL, Pinder SE, Laskey RA, Coleman N (2004) Geminin predicts adverse clinical outcome in breast cancer by reflecting cell-cycle progression. J Pathol 204: 121-130
14. Guida T, Salvatore G, Faviana P, Giannini R, Garcia-Rostan G, Provitera L, Basolo F, Fusco A, Carlomagno F, Santoro M (2005) Mitogenic effects of the up-regulation of minichromosome maintenance (MCM) proteins in anaplastic thyroid carcinoma. J Clin Endocrinol Metab 190: 4703-4709
15. Heidebrecht HJ, Adam-Klages S, Szczepanowski M, Pollmann M, Buck F, Endl E, Kruse ML, Rudolph P, Parwaresch R (2003) repp86: a human protein associated in the progression of mitosis. Mol Cancer Res 1: 271-279
16. Heidebrecht HJ, Buck F, Endl E, Kruse ML, Adam-Klages S, Andersen K, Frahm SO, Schulte C, Wacker HH, Parwaresch R (2001) Ki-Mcm6, a new monoclonal antibody specific to Memo: comparison of the distribution profile of Mcm6 and the Ki-67 antigen. Lab Invest 81: 1163-1165
17. Heidebrecht HJ, Buck F, Steinmann J, Sprenger R, Wacker HH, Parwaresch R (1997) p100: a novel proliferation-associated nuclear protein specifically restricted to cell cycle phases S, G2, and M. Blood 90: 226-233
18. Helfenstein A, Frahm SO, Krams M, Drescher W, Parwaresch R, Hassenpflug J (2004) Minichromosome maintenance protein (MCM6) in low-grade chondrosarcoma: distinction from enchondroma and identification of progressive tumors. Am J Clin Pathol 122: 912-918
19. Hodgson B, Li A, Tada S, Blow JJ (2002) Geminin becomes activated as an inhibitor of Cdt1/RLF-B following nuclear import. Curr Biol 12: 678-683
20. Hunter T, Pines J (1994) Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 79: 573-582
21. Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press
22. Kodani I, Osaki M, Shomori K, Araki K, Goto E, Ryoke K, Ito H (2003) Minichromosome maintenance 2 expression is correlated with mode of invasion and prognosis in oral squamous cell carcinomas. J Oral Pathol Med 32: 468-474
23. Labib K, Kearsey SE, Diffley JF (2001) MCM2-7 proteins are essential components of prereplicative complexes that accumulate cooperatively in the nucleus during G1-phase and are required to establish, but not maintain, the S-phase checkpoint. Mol Biol Cell 12: 3658-3667
24. Lardelli P, Bookman MA, Sundeen J, Longo DL, Jaffe ES (1990) Lymphocytic lymphoma of intermediate differentiation. Morphologic and immunophenotypic spectrum and clinical correlations. Am J Surg Pathol 14: 752-763
25. Li SS, Xue WC, Khoo US, Ngan HY, Chan KY, Tam IY, Chiu PM, Ip PP, Tam KF, Cheung AN (2005) Replicative MCM7 protein as a proliferation marker in endometrial carcinoma: a tissue microarray and clinicopathological analysis. Histopathology 46: 307-313
26. Lindner K, Gregan J, Montgomery S, Kearsey SE (2002) Essential role of MCM proteins in premeiotic DNA replication. Mol Biol Cell 13: 435-444
27. Lygerou Z, Nurse P (2000) Cell cycle. License withheld - geminin blocks DNA replication. Science 290: 2271-2273
28. Madine M, Laskey R (2001) Geminin bans replication licence. Nat Cell Biol 3: E49-E50
29. Martinez N, Camacho FI, Algara P, Rodriguez A, Dopazo A, Ruiz-Ballesteros E, Martin P, Martinez-Climent JA, Garcia-Conde J, Menarguez J, Solano F, Mollejo M, Piris MA (2003) The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res 63: 8226-8232
30. Meng MV, Grossfeld GD, Williams GH, Dilworth S, Stoeber K, Mulley TW, Weinberg V, Carroll PR, Tlsty TD (2001) Minichromosome maintenance protein 2 expression in prostate: characterization and association with outcome after therapy for cancer. Clin Cancer Res 7: 2712-2718
31. Meusers P, Engelhard M, Bartels H, Binder T, Fulle HH, Gorg K, Gunzer U, Havemann K, Kayser W, Konig E (1989) Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol 7: 365-380
32. Obermann EC, Eward KL, Dogan A, Paul EA, Loddo M, Munson P, Williams GH, Stoeber K (2005) DNA replication licensing in peripheral B-cell lymphoma. J Pathol 205: 318-328
33. Ogawa Y, Takahashi T, Masukata H (1999) Association of fission yeast Orp1 and Mcm6 proteins with chromosomal replication origins. Mol Cell Biol 19: 7228-7236
34. Ott G, Kalla J, Ott MM, Schryen B, Katzenberger T, Muller JG, Muller-Hermelink HK (1997) Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood 89: 1421-1429
35. Padmanabhan V, Callas P, Philips G, Trainer TD, Beatty BG (2004) DNA replication regulation protein Mcm7 as a marker of proliferation in prostate cancer. J Clin Pathol 57: 1057-1062
36. Ramnath N, Hernandez FJ, Tan DF, Huberman JA, Natarajan N, Beck AF, Hyland A, Todorov IT, Brooks JS, Bepler G (2001) MCM2 is an independent predictor of survival in patients with non-small-cell lung cancer. J Clin Oncol 19: 4259-4266
37. Raty R, Franssila K, Joensuu H, Teerenhovi L, Elonen E (2002) Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur J Haematol 69: 11-20
38. Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Fisher RI, Miller TP, LeBlanc M, Ott G, Kvaloy S, Holte H, Delabie J, Staudt LM (2003) The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3: 185-197
39. Schrader C, Janssen D, Meusers P, Brittinger G, Siebmann JU, Parwaresch R, Tiemann M (2005) Repp86: a new prognostic marker in mantle cell lymphoma. Eur J Haematol, in press
40. Schrader C, Meusers P, Brittinger G, Teymoortash A, Siebmann JU, Janssen D, Parwaresch R, Tiemann M (2004) Topoisomerase IIalpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome. Leukemia 18: 1200-1206
41. Scott IS, Heath TM, Morris LS, Rushbrook SM, Bird K, Vowler SL, Arends MJ, Coleman N (2004) A novel immunohistochemical method for estimating cell cycle phase distribution in ovarian serous neoplasms: implications for the histopathological assessment of paraffin-embedded specimens. Br J Cancer 90: 1583-1590
42. Stoeber K, Tlsty TD, Happerfield L, Thomas GA, Romanov S, Bobrow L, Williams ED, Williams GH (2001) DNA replication licensing and human cell proliferation. J Cell Sci 114: 2027-2041
43. Tachibana KE, Gonzalez MA, Coleman N (2005) Cell-cycle-dependent regulation of DNA replication and its relevance to cancer pathology. J Pathol 205: 123-129
44. Tsujimoto Y, Yunis J, Onorato-Showe L, Erikson J, Nowell PC, Croce CM (1984) Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. Science 224: 1403-1406
45. Velders GA, Kluin-Nelemans JC, de BC, Hermans J, Noordijk EM, Schuuring E, Kramer MH, Van DW, Rahder JB, Kluin PM, van KJ (1996) Mantle-cell lymphoma: a population-based clinical study. J Clin Oncol 14: 1269-1274
46. Wharton SB, Chan KK, Anderson JR, Stoeber K, Williams GH (2001) Replicative Mcm2 protein as a novel proliferation marker in oligodendrogliomas and its relationship to Ki67 labelling index, histological grade and prognosis. Neuropathol Appl Neurobiol 27: 305-313
47. Wharton SB, Hibberd S, Eward KL, Crimmins D, Jellinek DA, Levy D, Stoeber K, Williams GH (2004) DNA replication licensing and cell cycle kinetics of oligodendroglial tumours. Br J Cancer 91: 262-269
48. Wohlschlegel JA, Dwyer BT, Dhar SK, Cvetic C, Walter JC, Dutta A (2000) Inhibition of eukaryotic DNA replication by geminin binding to Cdt1. Science 290: 2309-2312